Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.
Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.
Black and Latina women who follow guidelines on nutrition and physical activity have a lower risk of developing breast, colorectal, and other obesity-related cancers.
Improving cancer outcomes via improved prevention and early detection and treatment, and better educating oncologists to implement the latest discoveries, will be the focus of the ESMO Congress 2022.